The rare-disease drug specialist ViroPharma ($VPHM) has been generating buyout buzz all week after reports that the company brought on the services of Goldman Sachs to hunt for potential acquisition offers. Sanofi ($SNY) and Shire ($SHPG), two major players in the rare disease arena, have reportedly taken an interest in ViroPharma, Bloomberg reports. And JMP Group thinks that the company, which closed at $40 per share earlier this week, could be sold for $60 a share. Article